Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2024-06-06 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
集团资金管理制度
Governance Information Classification · 95% confidence The document is titled '集团资金管理制度' (Group Funds Management System) and details internal policies and procedures for managing the company's and its subsidiaries' funds, including budgeting, account management, fund allocation, and risk management. It is a governance or internal control document rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements, audit opinions, or shareholder meeting information. It is a policy document issued by the company, likely approved by the board, describing governance practices related to funds management. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 2295 characters, which is relatively short but contains substantive policy content, not just an announcement or certification, so it is not RPA or RNS.
2024-06-06 Chinese
筹融资管理办法
Capital/Financing Update Classification · 90% confidence The document is titled '筹融资管理办法' which translates to 'Financing Management Measures' or 'Capital/Financing Management Rules' for 启迪药业集团股份公司. It outlines internal policies and procedures for managing the company's financing activities, including borrowing, issuing securities, approval processes, and post-financing management. It is a governance or management internal policy document rather than a report of financial results, audit, or announcement of a transaction. It does not contain financial statements or data, nor is it an announcement of a report or voting results. It is a regulatory or internal governance document related to capital management. The best fitting category is Capital/Financing Update (CAP) as it deals with the management and procedures of financing activities within the company.
2024-06-06 Chinese
关于召开2023年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2023 Annual General Meeting (AGM) of the company, including the date, time, venue, agenda items, voting procedures, and proxy forms. It does not contain the actual annual report or financial statements but rather the announcement and logistical details for the shareholders' meeting. The document length is 4412 characters, which is relatively short and consistent with a meeting notice rather than a full report. The document explicitly states it is a "通知" (notice) about the 2023 Annual General Meeting. Therefore, this document fits the category of AGM Information (AGM-R).
2024-06-06 Chinese
关于拟续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement by a company about the proposed reappointment of an accounting firm (audit firm) for the upcoming fiscal year. It details the qualifications, independence, and integrity of the audit firm, the audit committee's and board's approval process, and states that the appointment is subject to shareholder approval. The document does not contain any financial statements or audit results itself, nor is it a full audit report. It is a formal announcement related to audit services, specifically about the appointment of the auditor. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related audit information excluding full annual reports. The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it is announcing the auditor appointment. Therefore, the correct classification is AR with high confidence. FY 2024
2024-06-06 Chinese
反舞弊制度
Governance Information Classification · 95% confidence The document is titled '反舞弊制度' which translates to 'Anti-Fraud Policy' or 'Anti-Fraud System' of 启迪药业集团股份公司 (Qidi Pharmaceutical Group Co., Ltd.). It outlines the company's internal anti-fraud policies, responsibilities, definitions of fraud, prevention and control measures, reporting and investigation procedures, and disciplinary actions. There is no indication that this is a financial report, audit report, earnings release, or any other financial filing. It is a governance-related document detailing internal rules and procedures for fraud prevention and control. It is not a report publication announcement or a short notice but a substantive policy document. Therefore, the most appropriate classification is Governance Information (CGR).
2024-06-06 Chinese
2023年度股东大会会议资料
AGM Information Classification · 95% confidence The document is titled '2023年度股东大会 会议资料' which translates to '2023 Annual General Meeting (AGM) Meeting Materials'. It contains detailed agenda items for the 2023 AGM, including the reading and discussion of the 2023 Annual Report, Board and Supervisory reports, financial statements, profit distribution proposals, and other governance matters. The document includes procedural details about the meeting, voting instructions, and presentations of various reports for shareholder approval. It is clearly a set of materials prepared for and used during the Annual General Meeting rather than the Annual Report itself or an announcement of a report. The length (15,000 characters) and content confirm it is not a brief announcement or a certification. Therefore, the document fits the category of AGM Information (AGM-R).
2024-06-06 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.